Trial · NCT04201262
Results by group38
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 38
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With an Adjudicated On-trial Relapse in the Primary Treatment Period | Ravulizumab | 0 | Participants | ||
| Number of Participants With an Adjudicated On-trial Relapse in the Primary Treatment Period | Placebo (ECU-NMO-301) | 20 | Participants | ||
| Adjudicated On-trial Annualized Relapse Rate (ARR) in the Primary Treatment Period | Ravulizumab | 0.000 | 95% Confidence Interval NA to NA | relapses/year on study | |
| Adjudicated On-trial Annualized Relapse Rate (ARR) in the Primary Treatment Period | Placebo (ECU-NMO-301) | 0.350 | 95% Confidence Interval 0.199 to 0.616 | relapses/year on study | |
| Number of Participants With Clinically Important Change From Baseline in Hauser Ambulation Index (HAI) Score at the End of Primary Treatment Period | Ravulizumab | Clinical Improvement | 4 | Participants | |
| Number of Participants With Clinically Important Change From Baseline in Hauser Ambulation Index (HAI) Score at the End of Primary Treatment Period | Placebo (ECU-NMO-301) | Clinical Improvement | 4 | Participants | |
| Number of Participants With Clinically Important Change From Baseline in Hauser Ambulation Index (HAI) Score at the End of Primary Treatment Period | Ravulizumab | Stable | 52 | Participants | |
| Number of Participants With Clinically Important Change From Baseline in Hauser Ambulation Index (HAI) Score at the End of Primary Treatment Period | Placebo (ECU-NMO-301) | Stable | 32 | Participants | |
| Number of Participants With Clinically Important Change From Baseline in Hauser Ambulation Index (HAI) Score at the End of Primary Treatment Period | Ravulizumab | Clinical Worsening | 2 | Participants | |
| Number of Participants With Clinically Important Change From Baseline in Hauser Ambulation Index (HAI) Score at the End of Primary Treatment Period | Placebo (ECU-NMO-301) | Clinical Worsening | 11 | Participants | |
| Change From Baseline in European Quality of Life Health 5-dimension Questionnaire (EQ-5D) Index Score at the End of Primary Treatment Period | Ravulizumab | 0.005 | Standard Deviation 0.1522 | units on a scale | |
| Change From Baseline in European Quality of Life Health 5-dimension Questionnaire (EQ-5D) Index Score at the End of Primary Treatment Period | Placebo (ECU-NMO-301) | -0.043 | Standard Deviation 0.2115 | units on a scale | |
| Change From Baseline in EQ-5D Visual Analog Scale (VAS) Score at the End of Primary Treatment Period | Ravulizumab | 2.6 | Standard Deviation 14.07 | units on a scale | |
| Change From Baseline in EQ-5D Visual Analog Scale (VAS) Score at the End of Primary Treatment Period | Placebo (ECU-NMO-301) | 0.6 | Standard Deviation 16.39 | units on a scale | |
| Number of Participants With Clinically Important Worsening From Baseline in Expanded Disability Status Scale (EDSS) Score at the End of Primary Treatment Period | Ravulizumab | No clinically important worsening | 52 | Participants | |
| Number of Participants With Clinically Important Worsening From Baseline in Expanded Disability Status Scale (EDSS) Score at the End of Primary Treatment Period | Placebo (ECU-NMO-301) | No clinically important worsening | 36 | Participants | |
| Number of Participants With Clinically Important Worsening From Baseline in Expanded Disability Status Scale (EDSS) Score at the End of Primary Treatment Period | Ravulizumab | Clinically important worsening | 6 | Participants | |
| Number of Participants With Clinically Important Worsening From Baseline in Expanded Disability Status Scale (EDSS) Score at the End of Primary Treatment Period | Placebo (ECU-NMO-301) | Clinically important worsening | 11 | Participants | |
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs Leading to Study Drug Discontinuation in the Primary Treatment Period | Ravulizumab | Any TEAEs | 53 | Participants | |
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs Leading to Study Drug Discontinuation in the Primary Treatment Period | Placebo (ECU-NMO-301) | Any TEAEs | 45 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04201262/results